Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Wounds ; 32(8): 208-216, 2020 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-32804659

RESUMEN

INTRODUCTION: Biofilm in chronic wounds impedes the wound healing process. Each biofilm has differing characteristics requiring a multifaceted approach for removal while maintaining a surrounding environment conducive to wound healing. OBJECTIVE: In this study, 3 of the components in a wound cleanser are tested to determine synergy in eradicating biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa in vitro. MATERIALS AND METHODS: The 3 components assessed for synergy were ethylenediamine tetraacetic acid sodium salts (EDTA), vicinal diols (VD; ethylhexylglycerin and octane-1,2-diol), and polyhexamethylene biguanide (PHMB). Each component was assessed individually and in combination while dissolved in a base solution. The Calgary assay method was used for biofilm growth and treatment. Kull Equation analysis for synergy was conducted using viable count results. RESULTS: Synergy is defined as the interaction of components to produce a combined effect greater than the sum of their separate effects. The base solution containing all 3 components (EDTA, VD, and PHMB) reduced biofilm viability by more than 5 logs, demonstrating statistically significant synergy. The 3 components tested individually in the base solution resulted in the following: EDTA did not reduce bacteria viability; VD reduced viability by about 1 log; and PHMB reduced P aeruginosa viability by about 2.5 logs and MRSA viability by about 4 logs. Of importance, the MRSA biofilm failed to regrow in the recovery plates after combined treatment, indicating complete elimination of the biofilm bacteria. CONCLUSIONS: The experimental and calculated results indicate the 3 components (VD, EDTA, and PHMB) when used together act synergistically to eradicate MRSA and P aeruginosa biofilms in vitro.


Asunto(s)
Biguanidas/uso terapéutico , Biopelículas/efectos de los fármacos , Detergentes/uso terapéutico , Ácido Edético/uso terapéutico , Éteres de Glicerilo/uso terapéutico , Octanoles/uso terapéutico , Piel/efectos de los fármacos , Heridas y Lesiones/tratamiento farmacológico , Biguanidas/administración & dosificación , Detergentes/administración & dosificación , Sinergismo Farmacológico , Ácido Edético/administración & dosificación , Éteres de Glicerilo/administración & dosificación , Humanos , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Octanoles/administración & dosificación , Pseudomonas aeruginosa/efectos de los fármacos , Piel/microbiología , Heridas y Lesiones/microbiología
2.
Mar Drugs ; 8(8): 2267-300, 2010 Aug 05.
Artículo en Inglés | MEDLINE | ID: mdl-20948908

RESUMEN

Scandinavian folk medicine used shark liver oil for the treatment of cancers and other ailments based on the rarity of tumors in sharks and their ability to resist infections. Shark liver oil is a source of alkylglycerols which have been studied as anti-cancer agents in several clinical trials. Moreover, alkylglycerols have been investigated for the treatment of radiation induced side effects and for their ability to boost the immune system. Several experimental studies have shown the ability of alkylglycerols to open the blood brain barrier to facilitate the access of therapeutic drugs to the central nervous system. This review covers the most important studies of alkylglycerols in both animals and humans.


Asunto(s)
Antineoplásicos/uso terapéutico , Aceites de Pescado/uso terapéutico , Glicerol/análogos & derivados , Glicerol/uso terapéutico , Éteres de Glicerilo/uso terapéutico , Sistema Inmunológico/efectos de los fármacos , Neoplasias/tratamiento farmacológico , Animales , Antineoplásicos/química , Antineoplásicos/inmunología , Barrera Hematoencefálica/efectos de los fármacos , Ensayos Clínicos como Asunto , Aceites de Pescado/química , Aceites de Pescado/inmunología , Glicerol/administración & dosificación , Glicerol/química , Éteres de Glicerilo/administración & dosificación , Éteres de Glicerilo/química , Humanos , Neoplasias/radioterapia , Traumatismos por Radiación/prevención & control , Tiburones , Escualeno/uso terapéutico
3.
Mol Genet Metab ; 99(4): 408-16, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20060764

RESUMEN

Rhizomelic chondrodysplasia punctata type 1 is a peroxisome biogenesis disorder with the clinical features of rhizomelia, abnormal epiphyseal calcifications, congenital cataracts, and profound growth and developmental delays. It is a rare autosomal recessive disorder, caused by defects in the peroxisome receptor, PEX7. The pathology results from a deficiency of plasmalogens, a critical class of ether phospholipids whose functions are largely unknown. To study plasmalogens in an animal model, avoid early mortality and facilitate therapeutic investigations in this disease, we engineered a hypomorphic mouse model in which Pex7 transcript levels are reduced to less than 5% of wild type. These mice are born in expected ratios, are fertile and have a normal life span. However, they are petite and develop early cataracts. Further investigations showed delayed endochondral ossification and abnormalities in lens fibers. The biochemical features of reduced Pex7 function were reproduced in this model, including tissue plasmalogen deficiency, phytanic acid accumulation, reduced import of Pex7 ligands and consequent defects in plasmalogen biosynthesis and phytanic acid oxidation. Dietary supplementation with batyl alcohol, a plasmalogen precursor, recovered ether phospholipids in blood, but did not alter the clinical phenotype. The relatively mild phenotype of these mice mimics patients with milder PEX7 defects, and highlights the skeleton and lens as sensitive markers of plasmalogen deficiency. The role of plasmalogens in the normal function of these tissues at various ages can now be studied and additional therapeutic interventions tested in this model.


Asunto(s)
Huesos/metabolismo , Condrodisplasia Punctata Rizomélica/genética , Modelos Animales de Enfermedad , Cristalino/patología , Peroxisomas/fisiología , Plasmalógenos/metabolismo , Receptores Citoplasmáticos y Nucleares/deficiencia , Animales , Células Cultivadas , Condrodisplasia Punctata Rizomélica/terapia , Suplementos Dietéticos , Éteres de Glicerilo/uso terapéutico , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Receptor de la Señal 2 de Direccionamiento al Peroxisoma , Fenotipo , Ácido Fitánico/metabolismo , Distribución Tisular
4.
Ugeskr Laeger ; 153(5): 343-6, 1991 Jan 28.
Artículo en Danés | MEDLINE | ID: mdl-1994557

RESUMEN

Alkoxyglycerol derived from shark liver oil is marketed in Denmark and mentioned in popular articles as a supplementary agent in the treatment of cancer. A questionnaire investigation carried out in the Department of Oncology and Haematology in Odense Hospital revealed that approximately 1/3 of the patients in active neoplastic therapy employed shark liver oil preparations. The clinical investigations of alkoxyglycerol were all carried out on patients with cancer of the uterine cervix. All of the investigations were carried out by the same Swedish research group. Only a minority of the experimental material was blinded. No documentation was found for inhibited tumour growth or reduced mortality resulting from treatment with alkoxyglycerol. The number of cases of irradiation damage were found to be fewer in the groups treated with alkoxyglycerol, but the difference may be partially explained by different subdivision into stages. Alkoxyglycerol results in increase in the leukocyte and thrombocyte counts while higher or lower doses have, apparently, the opposite effect. The available literature concerning the clinical effect of alkoxyglycerol is limited and unsystematic and does not support the employment of alkocyglycerol in the treatment of cancer.


Asunto(s)
Aceites de Pescado/uso terapéutico , Éteres de Glicerilo/uso terapéutico , Neoplasias del Cuello Uterino/tratamiento farmacológico , Animales , Femenino , Humanos , Recuento de Leucocitos/efectos de los fármacos , Recuento de Plaquetas/efectos de los fármacos , Tiburones , Neoplasias del Cuello Uterino/sangre , Neoplasias del Cuello Uterino/mortalidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA